Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

Cancer Immunology Immunotherapy

Volumn 47, Issue 2, 1998, Pages 72-80

  Nagai, Eishi ^a   Ogawa, Takahiro ^a   Kielian, Tammy ^a   Ikubo, Akashi ^a   Suzuki, Tsuneo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Cancer; GM CSF gene; Therapy; Vaccine

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADENOVIRUS; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

3T3 CELLS; ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; COLONIC NEOPLASMS; DNA, COMPLEMENTARY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INTERFERON TYPE II; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 0031689298     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050506     Document Type: Article

References (55)

1. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H (1995) Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparisoin of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 121:587
2. Abel-Vahab ZA, Osanto S, Darrow TL, Barber JR, Vervaert CE, Gangavalli R, McCallister TJ, Seigler HF (1994) Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther 1:171
3. Adams DO (1989) Molecular interactions in macrophage activation. Immunol Today 10:33
4. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL (1995) Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunitry in a murine breast cancer model. Proc Natl Acad Sci USA 92:8522
5. Addison CL, Gauldie J, Muller WJ, Graham FL (1995) An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces remission in a murine breast cancer model. Int J Oncol 7:1253
6. Allione A, Consalvo M, Nanni P (1994) Immunization and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022
7. Arca MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE (1996) Diverse manifestations of tumroigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 42:237
8. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, Parmiani G, Cascinelli N (1993) Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor infiltrating lymphocytes (TIL) selected in vitro with low doses of IL-2. Cancer Immunol Immunother 36:315
9. Arienti F, Sule-Suso J, Melani C, Maccali C, Belli F, Illeni MT, Anichini A, Cascinelli N, Colombo MP, Parmiani G (1994) Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther 5:1139
10. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC (1996) Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56:2191
11. Bausero MA, Panoskaltsis-Mortari A, Blazer BR, Katsanis E (1996) Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. J Immunother 19:113
12. Bernasconi S, Matteucci C, Sironi M, Conni M, Colotta F, Mosca M, Colombo N, Bonazzi C, Landoni F, Corbetta G, Mantovani A, Allavena P (1995) Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 60:300
13. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC, Mulé JJ (1996) Clinical protocol. Adoptive immunotherapy of cancer with activated lymphnode cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 7:773
14. Chen GH, Curtis JL, Mody CH, Christensen PJ, Armstrong LR, Toews GB (1994) Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol 152:724
15. Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W (1991) In vivo depletion of CD4- and CD8-specific T cells. Current protocols in Immunology. Supplement 1, unit 4.1. Green and Wiley-Interscience, New York
16. Descamps V, Duffour M-T, Mathieu M-C, Fernadez N, Cordier L, Abina MA, Kremer E, Perricaudet M, Haddada H (1996) Strategies for cancer gene therapy using adenoviral vectors. J Mol Med 74:183
17. Dialynas DM, Quan ZS, Wall KA, Pierres A, Quintas J, Loken MR, Pierres M, Fitch F (1983) Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK 1.5: similarly of L3T4 to the human Leu-3/T4 molecule. J Immunol 131:2445
18. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating-factor stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
19. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, and Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
20. Gao X, Chen G, Zhang W, Tao Q, Yu Y, Ye T (1996) Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3:421
21. Graham FL, Prevec L (1995) Methods for construction of adenovirus vectors. Mol Biotechnol 3:207
22. Hollingsworth SJ, Darling D, Gaken J, Hirst W, Patel P, Kuiper M, Towner P, Humphreys S, Farzaneh F, Mufti GJ (1996) The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. Br J Cancer 74:6
23. Kaido T, Bandu MT, Maury C, Kerrantini M, Bellardelli F, Gresser I (1995) IFN-alpha gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA 2 mice and decreases their tumorigenicity in syngeneic C57BL 6 mice. Int J Cancer 60:221
24. Krauss JC, Strome SE, Chang AE, Shu S (1994) Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother 16:77
25. Krauss JC, Cameron MJ, Park AN, Forslund K, Chang AE (1995) Efficient transduction of early passage human melanoma to secrete IL-4. J Immunol Methods 183:239
26. Levitsky HI, Motgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guamieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor transduced, but nor B7-1-transduced, lymphoma cells primes idiotype-specilic T cells and generates potent systemic antitumor immunity. J Immunol 156:3858
27. 2+ influx, synergism with platelet activating factor, and significance for chemotaxis. J Biol Chem 269:4746
28. Maass G, Schweighoffer T, Berger M, Schmisdt W, Herbst E, Zatloukal K, Buschle M, Birnstiel ML (1995) Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo. Int J Immunopharmacol 17:65
29. MacKiewicz A, Wiznerowicz M, Roeb E, Nowak J, Pawlowski T, Braumann H, Heirich PC, Rose-John S (1995) Interleukin-6 type cytokines and their receptors for gene therapy of melanoma. Ann NY Acad Sci 762:361
30. Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang N-S (1996) Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine. Hum Gene Ther 7:1535
31. Matsushima K, Larson CG, DuBois GC, Oppenheim JJ (1989) Purification and characterization of a novel monocyte chemotaclic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169:1485
32. Melani C, Chiodoni C, Arienti F, Maccalli C, Sule-Suso J, Anichini A, Clombo MP, Parmiani G (1994) Cytokine gene transduction in tumor cells: Interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. Nat Immun 13.76
33. Melani C, Sulé-Suso J, Arienti F, Maccalli C, Passerini F, Colombo MP, Parmiani G (1995) A human melanoma cell line transduced with interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. Hum Gene Ther 6:1427
34. Metcalf D (1985) The granulocyte-macrophage colony stimulating factor. Science 229:16
35. Missol E, Sochanik A, Szala S (1995) Introduction of murine IL-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett 6:189
36. Morton DL, Foshg LJ, Hoon DSB, Nizze A, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashov R, Irie RF (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482.
37. Ogasawara M, Rosenberg SA (1993) Enhanced expression of HLA molecules and stimulation of autologous human infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res 53:3561
38. Ohira T, Ohe Y, Heike Y, Podack ER, Olsen KJ, Nishio K, Nishio M, Funayama Y, Ogasawara H, Arioka H, Kunikane H, Fukuda M, Kato H, Saijo N (1994) In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. J Cancer Res Clin Oncol 120:631
39. Pace JL, Russell SW (1981) Activation of mouse macrophages lor tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol 126:1863
40. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L (1995) Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of post surgical established lung metastases. Cancer Res 55:4941
41. Qin H-X, Chatterjee SK (1996) Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. Gene Ther 3:59
42. Rollins BJ, Morrison ED, Stiles CD (1988) Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 85:3738
43. Rollins HJ, Walz A, Bagiolini M (1991) Recombinant human MCP-1 JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78:1112
44. Rosenberg SA, Packard B, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JA, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei SP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676
45. Salup RR, Herberman RB, Wiltrout RH (1985) Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol 134:1236
46. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW (1994) Demonstration of a rational strategy for human proslate cancer gene therapy. J Urol 151:622
47. Sarmiento M, Glasebrook AH, Hitch FW (1980) IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing LYT2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665
48. Schmidt W, Schweghoffer T, Herbst E, Maass G, Berger M, Scilcher F, Schaffner G, Birnstiel ML (1995) Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 92:4711
49. Schmidt-Wolf IG, Huhn D, Neubauer A, Willig B (1994) Interleukin-7 gene gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther 5:1161
50. Stanley E, Metcalf D, Sobieszczuk P, Gough NM, Dunn AR (1985) The structure and expression of the murine gene encoding granulocyte-macrophage colony stimulating factor: evidence for utilisation of alternative promoters. EMBO J 4:2569
51. Uchiyama A, Hoon DS, Morisaki T, Kaneda Y, Yuzuki DH, Morton DL (1993) Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 53:949
52. Vadhan-Raj S, Broxmeier HK, Hittelman WN (1992) Use of granulocyte-macrophage colony stimulating factor in hematopoetic disorders: biology and nature of response. Semin Hematol 29:4
53. Walsh P, Dorner A, Duke RC, Su LJ, Glode LM (1995) Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst 87:809
54. Watanabe Y, Sakata T (1988) Highly efficient action of autocrine mouse interferon-gamma expressed via a retroviral vector. Eur J Immunol 18:1627
55. Wilson JM (1993) Vehicles for gene therapy. Nature 365:691